USANA Health Sciences (NYSE:USNA – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.450-2.450 for the period, compared to the consensus earnings per share estimate of 2.500. The company issued revenue guidance of $850.0 million-$850.0 million, compared to the consensus revenue estimate of $861.9 million.
USANA Health Sciences Trading Down 1.6 %
USNA stock traded down $0.57 during midday trading on Tuesday, hitting $34.48. The company’s stock had a trading volume of 117,667 shares, compared to its average volume of 79,922. USANA Health Sciences has a 12 month low of $34.15 and a 12 month high of $56.02. The firm’s 50-day moving average is $38.10 and its 200-day moving average is $42.67. The company has a market cap of $656.88 million, a PE ratio of 10.69, a P/E/G ratio of 1.20 and a beta of 0.89.
USANA Health Sciences (NYSE:USNA – Get Free Report) last issued its earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). The business had revenue of $212.87 million during the quarter, compared to analysts’ expectations of $218.64 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same period last year, the firm posted $0.89 EPS. Analysts expect that USANA Health Sciences will post 2.5 earnings per share for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on USNA
Insider Buying and Selling
In related news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director John Turman Fleming sold 1,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the sale, the director now owns 2,503 shares in the company, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,940 shares of company stock valued at $311,670. 0.33% of the stock is owned by company insiders.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Read More
- Five stocks we like better than USANA Health Sciences
- Russell 2000 Index, How Investors Use it For Profitable Trading
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is the FTSE 100 index?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- When to Sell a Stock for Profit or Loss
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.